ADAGIO THERAPEUTICS INC's ticker is and the CUSIP is 00534A102. A total of 75 filers reported holding ADAGIO THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.49 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $11,817 | -68.3% | 11,254 | -63.8% | 0.00% | – |
Q1 2023 | $37,324 | -67.2% | 31,103 | -58.9% | 0.00% | – |
Q4 2022 | $113,637 | -61.1% | 75,758 | -19.0% | 0.00% | – |
Q3 2022 | $292,000 | -85.1% | 93,487 | -84.4% | 0.00% | – |
Q2 2022 | $1,963,000 | +146.0% | 598,413 | +241.5% | 0.00% | – |
Q1 2022 | $798,000 | -79.2% | 175,230 | -66.8% | 0.00% | -100.0% |
Q4 2021 | $3,828,000 | +540.1% | 527,131 | +3624.8% | 0.00% | – |
Q3 2021 | $598,000 | – | 14,152 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
M28 Capital Management LP | 6,398,250 | $20,986,000 | 23.53% |
Foresite Capital Management V, LLC | 1,431,826 | $4,696,000 | 3.28% |
Alphabet Inc. | 5,680,785 | $18,633,000 | 1.01% |
683 Capital Management, LLC | 3,603,637 | $11,820,000 | 0.84% |
Slate Path Capital LP | 3,735,000 | $12,251,000 | 0.76% |
Bain Capital Life Sciences Investors, LLC | 1,937,207 | $6,354,000 | 0.74% |
Rubric Capital Management LP | 1,812,347 | $5,944,000 | 0.31% |
Orbimed Advisors | 5,056,000 | $16,584,000 | 0.30% |
Newtyn Management, LLC | 400,875 | $1,315,000 | 0.25% |
Redmile Group, LLC | 1,920,960 | $6,301,000 | 0.24% |